drugset / Trial / NCT05294666
Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
It is planned to explore the efficacy and safety of local 0.05% cyclosporine eye drops in the treatment of chronic graft-versus-host eye disease. Through the comparative study with 0.1% tacrolimus eye drops, to clarify the short-term and long-term efficacy of 0.05% CSA in these patients, and to explore the benefits of long-term maintenance of local cyclosporine to patients.
Timeline
- Start
- 2020-04-01
- Primary completion
- 2021-06-01
- Completion
- 2021-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 0.05 % | Other |
| Subject | Tacrolimus | Small molecule | 0.05 % | Other |